Elicio Therapeutics Inc. (ELTX)
6.35
0.15 (2.42%)
At close: Jan 15, 2025, 3:43 PM
6.39
0.63%
After-hours Jan 15, 2025, 03:44 PM EST
undefined% (undefined)
| Bid | 6.2 |
| Market Cap | 68.52M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.44 |
| PE Ratio (ttm) | -1.85 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 9.89 |
| Volume | 18,335 |
| Avg. Volume (20D) | 26,445 |
| Open | 6.40 |
| Previous Close | 6.20 |
| Day's Range | 6.20 - 6.41 |
| 52-Week Range | 2.96 - 11.45 |
| Beta | undefined |
About ELTX
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 32
Stock Exchange NASDAQ
Ticker Symbol ELTX
Website https://elicio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ELTX stock is "Buy." The 12-month stock price forecast is $9.5, which is an increase of 49.61% from the latest price.
Buy 66.67%
Hold 0.00%
Sell 0.00%
6 months ago ·
Source
-40.35%
Elicio Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
6 months ago ·
Source
+6.99%
Elicio Therapeutics shares are trading lower after the company announced preliminary disease-free survival analysis from the Phase 1a study of ELI-002 7P, showing patients receiving ELI-002 7P at a dose of 4.9mg AMP-peptide had yet to reach the median DFS endpoint as of the May 24 cutoff date.
